Depressive symptoms and elevated C-reactive protein levels are common among individuals with schizophrenia, but little is known about the relationship between these factors. In a recent study, researchers...
While higher lifetime antipsychotic exposure has been associated with poorer cognition in patients with schizophrenia, the effects of adjunctive psychiatric medication use and lifetime trends are not well...
In a recent study, researchers compared the safety and efficacy of 2 drugs for adults with acute exacerbations of schizophrenia. To see results of the study, including which drugs were evaluated, read...
Schizophrenia patients taking antipsychotics face a greater risk of cardiovascular disease. In a recent study, researchers tested the effects of a glucagon-like peptide-1 receptor agonist in schizophrenia...
The findings of a recent study challenge the hypothesis that schizophrenia and other cognitive impairments are associated with GABA deficiency. The study compared the brain chemistry of schizophrenia...
In a new study, researchers aimed to determine the effects of a diabetes drug added to clozapine or olanzapine treatment for schizophrenia. To see the results, including how the drug affected...
Aristada recently received approval from the US Food and Drug Administration for a new and shorter dosing regimen, providing more options to patients and health care providers.
In a large-scale meta-analysis, researchers analyzed the prevalence and incidence of cardiovascular diseases and cardiovascular-related death in patients with severe mental illness and the general...
In the year following a new psychosis diagnosis, the death rate for young people is 24 times higher than for young people without psychosis, according to a new study published online in Schizophrenia...
An exaggerated emotional brain response to nonthreatening, nonemotional cues at age 14 predicted the onset of psychosis symptoms within the next 2 years.
